This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Comment: Illumina’s jurisdiction challenge in EU court may skirt the big question

By Natalie McNelis ( December 15, 2021, 10:12 GMT | Comment) -- Illumina’s challenge of the EU’s right to review its acquisition of Grail, to be heard in the EU's General Court tomorrow, could turn on the specifics of the case, rather than on the legality of the European Commission's novel use of the Article 22 referral route. If the court finds irregularities it could uphold Illumina's case without outlawing the use of the procedure, which the regulator says is important to catch "killer acquisitions."With Illumina’s challenge to the EU’s right to review its $8 billion acquisition of startup Grail reaching court tomorrow, the question of how the case might play out looms large....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login